In this phase II trial, newborns with moderate/severe encephalopathy and perinatal depression were randomly assigned to receive either EPO (1000 U/kg intravenously; n = 24) or a placebo (n = 26) at specific intervals in the first week of life. This evidence concerns the gene EPO and Encephalopathy.